{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T09:06:31Z","timestamp":1784538391202,"version":"3.55.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,20]]},"DOI":"10.7759\/cureus.112994","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T08:37:41Z","timestamp":1784536661000},"source":"Crossref","is-referenced-by-count":0,"title":["Safety and Efficacy of Atogepant for Migraine Prevention: A Systematic Review and Meta-Analysis of Randomized Controlled Trials"],"prefix":"10.7759","author":[{"given":"Samahir","family":"Akram Nizamani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramsha","family":"Memon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chinenye","family":"Iguh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roa","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Onuwabhagbe Daniel","family":"Omomhenle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathaniel Oluwakayode","family":"Oyedeji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadia","family":"Zafar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Austin","family":"Nwawueze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hurmat","family":"Amjad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul Sunday","family":"Samuel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daud","family":"Gul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-74253-3","article-title":"Different effects of migraine associated features on headache impact, pain intensity, and psychiatric conditions in patients with migraine","volume":"14","author":"Imai N","year":"2024","unstructured":"Imai N, Matsumori Y. Different effects of migraine associated features on headache impact, pain intensity, and psychiatric conditions in patients with migraine. Sci Rep. 2024, 14:22611. 10.1038\/s41598-024-74253-3","journal-title":"Sci Rep"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-022-00763-1","article-title":"Global epidemiology of migraine and its implications for public health and health policy","volume":"19","author":"Steiner TJ","year":"2023","unstructured":"Steiner TJ, Stovner LJ. Global epidemiology of migraine and its implications for public health and health policy. Nat Rev Neurol. 2023, 19:109-17. 10.1038\/s41582-022-00763-1","journal-title":"Nat Rev Neurol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1136\/bmjno-2023-000616","article-title":"Adverse and serious adverse events incidence of pharmacological interventions for managing chronic and episodic migraine in adults: a systematic review","volume":"6","author":"Naghdi S","year":"2024","unstructured":"Naghdi S, Underwood M, Brown A, et al.. Adverse and serious adverse events incidence of pharmacological interventions for managing chronic and episodic migraine in adults: a systematic review. BMJ Neurol Open. 2024, 6:e000616. 10.1136\/bmjno-2023-000616","journal-title":"BMJ Neurol Open"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s11916-015-0498-8","article-title":"Improving medication adherence in migraine treatment","volume":"19","author":"Seng EK","year":"2015","unstructured":"Seng EK, Rains JA, Nicholson RA, Lipton RB. Improving medication adherence in migraine treatment. Curr Pain Headache Rep. 2015, 19:24. 10.1007\/s11916-015-0498-8","journal-title":"Curr Pain Headache Rep"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/head.13529","article-title":"CGRP and the trigeminal system in migraine","volume":"59","author":"Iyengar S","year":"2019","unstructured":"Iyengar S, Johnson KW, Ossipov MH, Aurora SK. CGRP and the trigeminal system in migraine. Headache. 2019, 59:659-81. 10.1111\/head.13529","journal-title":"Headache"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1177\/03331024251370608","article-title":"Effectiveness and tolerability of atogepant as preventive treatment in resistant individuals with chronic migraine: six-month real-world evidence","volume":"45","author":"Russo A","year":"2025","unstructured":"Russo A, Silvestro M, Finkelstein I, et al.. Effectiveness and tolerability of atogepant as preventive treatment in resistant individuals with chronic migraine: six-month real-world evidence. Cephalalgia. 2025, 45:3331024251370608. 10.1177\/03331024251370608","journal-title":"Cephalalgia"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/head.14692","article-title":"Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: an American Headache Society position statement update","volume":"64","author":"Charles AC","year":"2024","unstructured":"Charles AC, Digre KB, Goadsby PJ, Robbins MS, Hershey A. Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: an American Headache Society position statement update. Headache. 2024, 64:333-41. 10.1111\/head.14692","journal-title":"Headache"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13707","article-title":"Atogepant: mechanism of action, clinical and translational science","volume":"17","author":"Boinpally R","year":"2024","unstructured":"Boinpally R, Shebley M, Trugman JM. Atogepant: mechanism of action, clinical and translational science. Clin Transl Sci. 2024, 17:e13707. 10.1111\/cts.13707","journal-title":"Clin Transl Sci"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.92.15_supplement.S17.001","article-title":"Orally administered atogepant was efficacious, safe, and tolerable for the prevention of migraine: results from a phase 2b\/3 study (S17.001)","volume":"92","author":"Goadsby PJ","year":"2019","unstructured":"Goadsby PJ, Dodick DW, Trugman JM, Finnegan M, Lakkis H, Lu K, Szegedi A. Orally administered atogepant was efficacious, safe, and tolerable for the prevention of migraine: results from a phase 2b\/3 study (S17.001). Neurology. 2019, 92:17.001. 10.1212\/WNL.92.15_supplement.S17.001","journal-title":"Neurology"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035908","article-title":"Atogepant for the preventive treatment of migraine","volume":"385","author":"Ailani J","year":"2021","unstructured":"Ailani J, Lipton RB, Goadsby PJ, et al.. Atogepant for the preventive treatment of migraine. N Engl J Med. 2021, 385:695-706. 10.1056\/NEJMoa2035908","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-022-01391-2","article-title":"The efficacy and safety of atogepant for the prophylactic treatment of migraine: evidence from randomized controlled trials","volume":"23","author":"Tao X","year":"2022","unstructured":"Tao X, Yan Z, Meng J, et al.. The efficacy and safety of atogepant for the prophylactic treatment of migraine: evidence from randomized controlled trials. J Headache Pain. 2022, 23:19. 10.1186\/s10194-022-01391-2","journal-title":"J Headache Pain"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1097\/JCMA.0000000000001070","article-title":"Update on gepants for the treatment of chronic migraine","volume":"87","author":"Aoh Y","year":"2024","unstructured":"Aoh Y, Hou TW, Yang CC, et al.. Update on gepants for the treatment of chronic migraine. J Chin Med Assoc. 2024, 87:350-6. 10.1097\/JCMA.0000000000001070","journal-title":"J Chin Med Assoc"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-050224-111631","article-title":"CGRP and migraine: real world insights and future therapeutic directions","volume":"77","author":"Russo AF","year":"2026","unstructured":"Russo AF, Kaiser EA. CGRP and migraine: real world insights and future therapeutic directions. Annu Rev Med. 2026, 77:415-32. 10.1146\/annurev-med-050224-111631","journal-title":"Annu Rev Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JA","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019, 366:l4898. 10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01049-8","article-title":"Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"402","author":"Pozo-Rosich P","year":"2023","unstructured":"Pozo-Rosich P, Ailani J, Ashina M, et al.. Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023, 402:775-85. 10.1016\/S0140-6736(23)01049-8","journal-title":"Lancet"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(24)00025-5","article-title":"Safety and efficacy of atogepant for the preventive treatment of episodic migraine in adults for whom conventional oral preventive treatments have failed (ELEVATE): a randomised, placebo-controlled, phase 3b trial","volume":"23","author":"Tassorelli C","year":"2024","unstructured":"Tassorelli C, Nagy K, Pozo-Rosich P, et al.. Safety and efficacy of atogepant for the preventive treatment of episodic migraine in adults for whom conventional oral preventive treatments have failed (ELEVATE): a randomised, placebo-controlled, phase 3b trial. Lancet Neurol. 2024, 23:382-92. 10.1016\/S1474-4422(24)00025-5","journal-title":"Lancet Neurol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1177\/03331024251374569","article-title":"Atogepant for the preventive treatment of episodic migraine in Japanese participants: a phase 2\/3, randomized, double-blind, placebo-controlled trial with an active treatment extension (RELEASE)","volume":"45","author":"Matsumori Y","year":"2025","unstructured":"Matsumori Y, Yamada H, Nagaseki Y, et al.. Atogepant for the preventive treatment of episodic migraine in Japanese participants: a phase 2\/3, randomized, double-blind, placebo-controlled trial with an active treatment extension (RELEASE). Cephalalgia. 2025, 45:3331024251374569. 10.1177\/03331024251374569","journal-title":"Cephalalgia"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30234-9","article-title":"Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b\/3 trial","volume":"19","author":"Goadsby PJ","year":"2020","unstructured":"Goadsby PJ, Dodick DW, Ailani J, Trugman JM, Finnegan M, Lu K, Szegedi A. Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b\/3 trial. Lancet Neurol. 2020, 19:727-37. 10.1016\/S1474-4422(20)30234-9","journal-title":"Lancet Neurol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000209584","article-title":"Efficacy of atogepant in chronic migraine with and without acute medication overuse in the randomized, double-blind, phase 3 PROGRESS trial","volume":"103","author":"Goadsby PJ","year":"2024","unstructured":"Goadsby PJ, Friedman DI, Holle-Lee D, et al.. Efficacy of atogepant in chronic migraine with and without acute medication overuse in the randomized, double-blind, phase 3 PROGRESS trial. Neurology. 2024, 103:e209584. 10.1212\/WNL.0000000000209584","journal-title":"Neurology"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.15499","article-title":"Rates of response to atogepant for migraine prophylaxis among adults: a secondary analysis of a randomized clinical trial","volume":"5","author":"Lipton RB","year":"2022","unstructured":"Lipton RB, Pozo-Rosich P, Blumenfeld AM, et al.. Rates of response to atogepant for migraine prophylaxis among adults: a secondary analysis of a randomized clinical trial. JAMA Netw Open. 2022, 5:e2215499. 10.1001\/jamanetworkopen.2022.15499","journal-title":"JAMA Netw Open"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-024-01822-2","article-title":"Efficacy and safety of atogepant, a small molecule CGRP receptor antagonist, for the preventive treatment of migraine: a systematic review and meta-analysis","volume":"25","author":"Hou M","year":"2024","unstructured":"Hou M, Luo X, He S, et al.. Efficacy and safety of atogepant, a small molecule CGRP receptor antagonist, for the preventive treatment of migraine: a systematic review and meta-analysis. J Headache Pain. 2024, 25:116. 10.1186\/s10194-024-01822-2","journal-title":"J Headache Pain"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-024-01736-z","article-title":"Safety and tolerability of atogepant for the preventive treatment of migraine: a post hoc analysis of pooled data from four clinical trials","volume":"25","author":"Rizzoli P","year":"2024","unstructured":"Rizzoli P, Marmura MJ, Robblee J, et al.. Safety and tolerability of atogepant for the preventive treatment of migraine: a post hoc analysis of pooled data from four clinical trials. J Headache Pain. 2024, 25:35. 10.1186\/s10194-024-01736-z","journal-title":"J Headache Pain"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1468961","article-title":"Atogepant for migraine prevention: a meta-analysis of safety and efficacy in adults","volume":"15","author":"Raja A","year":"2024","unstructured":"Raja A, Asim R, Shuja MH, et al.. Atogepant for migraine prevention: a meta-analysis of safety and efficacy in adults. Front Neurol. 2024, 15:1468961. 10.3389\/fneur.2024.1468961","journal-title":"Front Neurol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/508728-safety-and-efficacy-of-atogepant-for-migraine-prevention-a-systematic-review-and-meta-analysis-of-randomized-controlled-trials","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T08:37:42Z","timestamp":1784536662000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/508728-safety-and-efficacy-of-atogepant-for-migraine-prevention-a-systematic-review-and-meta-analysis-of-randomized-controlled-trials"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,20]]},"references-count":24,"URL":"https:\/\/doi.org\/10.7759\/cureus.112994","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,20]]}}}